IRIS
ROSELLI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 56.981
EU - Europa 4.027
AS - Asia 1.265
Continente sconosciuto - Info sul continente non disponibili 25
SA - Sud America 20
OC - Oceania 10
AF - Africa 5
Totale 62.333
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 56.958
UA - Ucraina 761
DE - Germania 740
IE - Irlanda 644
CN - Cina 631
IT - Italia 593
KR - Corea 270
FR - Francia 240
GB - Regno Unito 216
PL - Polonia 216
SG - Singapore 207
RU - Federazione Russa 174
SE - Svezia 171
FI - Finlandia 164
JP - Giappone 35
BE - Belgio 28
VN - Vietnam 24
IN - India 21
CA - Canada 20
EU - Europa 19
CZ - Repubblica Ceca 18
NL - Olanda 14
TW - Taiwan 14
ID - Indonesia 12
ES - Italia 10
HK - Hong Kong 10
RO - Romania 10
AU - Australia 9
BR - Brasile 8
CH - Svizzera 8
KG - Kirghizistan 7
CL - Cile 6
SA - Arabia Saudita 6
AT - Austria 5
TR - Turchia 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GR - Grecia 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
IR - Iran 3
NO - Norvegia 3
PH - Filippine 3
A1 - Anonimo 2
AM - Armenia 2
BD - Bangladesh 2
EC - Ecuador 2
HR - Croazia 2
KW - Kuwait 2
LT - Lituania 2
MN - Mongolia 2
PE - Perù 2
ZA - Sudafrica 2
AR - Argentina 1
BG - Bulgaria 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
EE - Estonia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MX - Messico 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 62.333
Salva come PNG Salva come JPEG
Città #
Woodbridge 16.968
Wilmington 15.628
Houston 14.960
Fairfield 1.700
Ann Arbor 1.039
Chandler 866
Ashburn 821
Seattle 695
Jacksonville 682
Cambridge 638
Dublin 573
Medford 432
Dearborn 296
Rome 266
Beijing 244
New York 220
Kraków 215
Lawrence 201
San Diego 141
Menlo Park 128
Singapore 126
Zhengzhou 94
Moscow 88
Engelhard 73
Mülheim 56
Milan 55
Saint Petersburg 49
London 47
Falls Church 46
Boardman 40
Nanjing 39
Norwalk 37
Hefei 34
Redwood City 34
Brussels 28
Shanghai 28
Mountain View 26
Detroit 23
Kunming 23
University Park 23
Guangzhou 22
Phoenix 22
Verona 21
Palo Alto 20
Hangzhou 19
Seoul 17
Dong Ket 16
Nürnberg 16
Brno 14
Los Angeles 14
Nanchang 14
Taipei 14
Toronto 13
Creede 11
Chicago 10
Monte Vista 10
Nuremberg 10
Turin 10
Tokyo 9
Bandung 8
Chengdu 8
Helsinki 8
Hounslow 8
Indiana 8
Jinan 8
Lappeenranta 8
San Jose 8
Hebei 7
Miami 7
Pune 7
Redmond 7
Shenyang 7
Wuhan 7
Bologna 6
Colle di Val d'Elsa 6
Columbus 6
Council Bluffs 6
Del Norte 6
Hanoi 6
Naples 6
Buffalo 5
Central District 5
San Francisco 5
San Mateo 5
Augusta 4
Baotou 4
Barcelona 4
Bari 4
Changsha 4
Colorado Springs 4
Durham 4
Fort Worth 4
Fremont 4
Hong Kong 4
Kilburn 4
Munich 4
Padova 4
Paris 4
Santa Clara 4
Amsterdam 3
Totale 58.195
Salva come PNG Salva come JPEG
Nome #
Role of serum and glucocorticoid-inducible kinase (SGK)-1 in senescence: a novel molecular target against age-related diseases 481
Sex-Genetic Interaction in the Risk for Cerebrovascular Disease 471
Pharmacogenomics and pharmacogenetics of thiazolidinediones: Role in diabetes and cardiovascular risk factors 460
Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma 459
Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers 452
Sample PREanalytical Code for labeling of biospecimens: an analysis of specimen labeling protocols 448
Impact of endoscopic ultrasound-guided fine-needle aspiration and multidisciplinary approach in the management of abdominal or mediastinal mass 430
Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies 424
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients 423
Butyryl-cholinesterase is related to muscle mass and strength. A new biomarker to identify elderly subjects at risk of sarcopenia 423
Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care) 422
Anti-angiogenic drugs, vascular toxicity and thromboembolism in solid cancer 422
Pathological classification of DCIS and planning of therapeutic management 419
Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice 418
Soluble selectin levels in patients with lung cancer 416
The incidence of hip, forearm, humeral, ankle, and vertebral fragility fractures in Italy: results from a 3-year multicenter study 414
Immune reaction and colorectal cancer: friends or foes? 414
Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients 414
Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer 414
Aging: an important risk factor in chemotherapy-associated vascular diseases 410
TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy 410
Prognostic value of glycated hemoglobin in colorectal cancer 410
Type 2 diabetes and breast cancer: The interplay between impaired glucose metabolism and oxidant stress 409
Ketogenic diet and other dietary intervention strategies in the treatment of cancer 409
Gender differences in cancer-associated venous thromboembolism 406
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer 406
Oxidant stress as a major determinant of platelet activation in invasive breast cancer 405
Functional impairment of activated protein C in breast cancer - relationship to survival outcomes 405
Clinical models and biochemical predictors of VTE in lung cancer 404
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 404
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies 403
Effects of conventional therapeutic interventions on the number and function of regulatory T cells 403
Prognostic value of carcinoembryonic antigen and vascular endothelial growth factor tumor tissue content in colorectal cancer 402
Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients--a pilot study 402
Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients 402
RISK: A random optimization interactive system based on kernel learning for predicting breast cancer disease progression 402
Day-surgical management of ductal carcinoma in situ (DCIS)of the breast using wide local excision with sentinel node biopsy 401
Minimal sentinel node procedure for staging early breast cancer 400
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer 400
RFID as a new ICT tool to monitor specimen life cycle and quality control in a biobank 399
Biological and predictive role of ERCC1 polymorphisms in cancer 399
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors 398
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio 398
Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 397
Obesity and colorectal cancer: role of adipokines in tumor initiation and progression 397
Thromboembolic events in patients treated with anti-angiogenic drugs 396
Chemoprevention of colonic cancer: is there a foreseeable future? 396
Sentinel lymphadenectomy in cutaneous melanoma 396
Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis 395
Risk assessment for venous thromboembolism in chemotherapy treated ambulatory cancer patients: a machine learning approach 395
Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience 393
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101) 391
Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients 391
Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy 391
Adjuvant chemotherapy for stage IB non-small cell lung cancer 389
Cardiac surgery with extracorporeal circulation in cancer patients: risk factors for late survival and cancer-related event-free survival 387
Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer 387
Postoperative adjuvant therapy for stage IB non-small-cell lung cancer 384
Family history of cancer in patients with gastric cancer 383
VEGF and VTE risk in cancer patients-letter 381
An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients 380
Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention 379
Prognostic value of vascular endothelial growth factor tumor tissue content of colorectal cancer 377
Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle 376
Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression 376
Prognostic value of soluble P-selectin levels in colorectal cancer 375
Monoclonal antibodies in gastrointestinal cancers 375
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer 374
Are there alternative ways to quantify the real benefit of novel agents in oncology? - The 'death pace' 372
Insulinemia and the risk of breast cancer and its relapse 371
VEGF gene promoter polymorphisms and risk of VTE in chemotherapytreated cancer patients 371
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients 370
Determinants of homocysteine levels in colorectal and breast cancer patients 370
Cardiac sarcomas: an update 370
Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab')2 (FO23C5) in CEA serum-negative colorectal cancer patients 370
Overexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis 370
Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer 370
Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: Pros and cons 370
In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts 365
The value of soluble selectin levels in the management of lung cancer patients 364
The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience 363
A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study 362
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis 362
The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy 361
Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin 361
Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer 360
Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation 359
Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy 357
Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro 356
The use of B72.3 second generation (CC) monoclonal antibody for the radioimmunolocalization of human carcinoma xenografts 355
Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients 355
Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet 353
Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study 353
Mutational analysis of gastrointestinal stromal tumors (GISTs): procedural approach for diagnostic purposes 352
Percutaneous cryoablation and vertebroplasty: a case report 351
[Ductal carcinoma in situ (DCIS): an always present reality; which treatment? Role of sentinel lymph node] 351
Predictive value of high-density lipoprotein (HDL)-cholesterol for cancer-associated venous thromboembolism during chemotherapy 350
Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia 350
CD26: a multi-purpose pharmacological target 350
Kallikrein-related peptidases targeted therapies in prostate cancer: Perspectives and challenges 350
Totale 39.116
Salva come PNG Salva come JPEG
Categoria #
all - tutte 120.480
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 120.480
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202015.655 0 1.292 1.274 1.507 1.527 1.906 1.509 1.491 1.507 1.333 1.069 1.240
2020/202110.145 1.056 1.214 1.006 1.250 1.209 1.163 1.387 1.003 223 191 353 90
2021/20222.313 111 241 84 105 98 178 212 181 146 259 166 532
2022/20232.465 266 205 60 275 237 597 207 163 190 36 162 67
2023/20241.064 109 34 59 43 98 245 155 51 23 33 7 207
2024/2025198 167 31 0 0 0 0 0 0 0 0 0 0
Totale 62.962